Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Titolo: | Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies |
Autori: | D'AGARO, PIERLANFRANCO [Membro del Collaboration Group] |
Data di pubblicazione: | 2018 |
Stato di pubblicazione: | Pubblicato |
Rivista: | |
Abstract: | Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. |
Handle: | http://hdl.handle.net/11368/2926783 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086 |
URL: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.9.18-00086 |
Appare nelle tipologie: | 1.1 Articolo in Rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
eurosurv-23-9-1.pdf | Documento in Versione Editoriale | ![]() | Open Access Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.